# Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

> **NCT07008638** · PHASE1,PHASE2 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 32 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- TP53

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** CPX-351

## Key facts

- **NCT ID:** NCT07008638
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-01-27
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07008638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07008638, "Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07008638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*